// Provide alternate content for browsers that do not support scripting // or for those that have scripting disabled. Alternate HTML content should be placed here. This content requires the Adobe Flash Player. Get Flash QVAR.com
Asthma Inflammation Extends Into Even the Smallest Airways1
  • The small (<2 mm)3 airways are a primary site of asthma inflammation1,2
  • Most inhaled corticosteroids (ICSs) aren’t formulated to get there
  • As a result, small-airway inflammation is typically uncontrolled1
For Your Asthma Patient, Uncontrolled Small-Airway Inflammation Could Mean:
  • Persistent symptoms1
  • Increased asthma exacerbations1
  • Small-airway anatomic changes, which can potentially lead to irreversible lung damage1
QVAR®: The Solution for Small-Airway Inflammation

Because Only QVAR Is a Small-Particle, Extra-Fine Aerosol Solution4
  • The small particle size of QVAR (MMAD of 1.1 µm) penetrates more effectively into the small
         airways than large-particle suspension formulations5
  • QVAR delivers a greater mass of small particles to the peripheral lung6
  • QVAR achieves high lung deposition of up to 58%*
    • - Compared with 12 to 13% for fluticasone CFC1,5,7
    • - Minimizes deposition in the mouth and throat5
    • - Distributes evenly throughout the entire lung5
QVAR’s Deposition Is Consistent Even When Inhaler Technique Is Poor7



QVAR’s Anti-inflammatory Treatment Reaches the Entire Lung5
box
    References:
  1. Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol. 2002;109(2):S447-S460.
  2. Yanai M, Sekizawa K, Ohrui T, et al. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol. 1992;72:1016-1023.
  3. Thongngarm T, Silkoff PE, Kossack WS, Nelson HS. Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma. J Asthma. 2005;42:257-263.
  4. Zeidler M, Corren J. Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma. Treat Respir Med. 2004;3(1):35-44.
  5. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone*: a cross-over study in healthy volunteers. Chest. 2002;122:510-516.
  6. Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thor Soc. 2004;1:356-363.
  7. Leach C. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol. 1999;104:S250–S252.
  8. Data on File. Teva Specialty Pharmaceuticals LLC.
080713
QVAR® is a registered trademark of IVAX Corporation, a member of the Teva Group.
©2008 Teva Specialty Pharmaceuticals LLC. This site is intended for U.S. healthcare professionals only.